A61K 40/15
Natural-killer [nk] cells
Official title: Natural-killer [NK] cells; Natural-killer T [NKT] cells
A61K40/15 (Natural-killer [nk] cells) appears on 536 US grants and 1,716 published applications in this corpus.
Search patents in A61K- Granted patents
- 536
- Published applications
- 1,716
- Assignees
- 638
- Inventors
- 3,030
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 0 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 1 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 2 | 0 |
| 2002 | 1 | 5 |
| 2003 | 1 | 7 |
| 2004 | 1 | 13 |
| 2005 | 0 | 3 |
| 2006 | 1 | 11 |
| 2007 | 0 | 9 |
| 2008 | 4 | 13 |
| 2009 | 3 | 11 |
| 2010 | 4 | 16 |
| 2011 | 6 | 17 |
| 2012 | 9 | 16 |
| 2013 | 5 | 16 |
| 2014 | 14 | 27 |
| 2015 | 17 | 26 |
| 2016 | 12 | 28 |
| 2017 | 17 | 44 |
| 2018 | 16 | 71 |
| 2019 | 18 | 87 |
| 2020 | 48 | 136 |
| 2021 | 40 | 137 |
| 2022 | 48 | 166 |
| 2023 | 61 | 179 |
| 2024 | 54 | 267 |
| 2025 | 91 | 218 |
| 2026 | 54 | 193 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Immune cells with enhanced cytotoxicity and methods of use thereof29 Sep 2026US 12,747,443 B2Ludwig Institute for Cancer Research
- K562 universal antigen presenting cells and uses thereof15 Sep 2026US 12,734,239 B2Board of Regents, The University of Texas System
- Transforming growth factor beta-resistant natural killer cells8 Sep 2026US 12,729,228 B2Research Institute At Nationwide Children's Hospital
- Media and methods for differentiating natural killer cells1 Sep 2026US 12,723,233 B2Stemcell Technologies Canada Inc.
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Antibody recruiting molecules for the treatment of coronavirus disease-198 Oct 2026US 2026/0306644 A1Biohaven Therapeutics Ltd.
- Multi-receptor natural killer cells8 Oct 2026US 2026/0308225 A1Board of Regents, The University of Texas System
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Methods of enhancing or modifying nk cells8 Oct 2026US 2026/0308525 A1Zelluna Immunotherapy AS
Most cited
By later US patents
- Chimeric receptors with 4-1BB stimulatory signaling domain329US 8,399,645 B2St. Jude Children?S Research Hospital · 2013
- Modified cell line and method for expansion of NK cell123US 7,435,596 B2St. Jude Children?S Research Hospital · 2008
- Ex vivo culture of stem cells105US 5,922,597 ARegents of the University of Minnesota · 1999
- Genetically modified human natural killer cell lines98US 7,618,817 B2Fox Chase Cancer Center · 2009
- Method of culturing lymphocytes and method of treatment using such lymphocytes88US 5,443,983 ARegents of the University of Minnesota · 1995